News

FDA may limit future COVID-19 boosters to seniors, those at higher risk for complications
US Food and Drug Administration officials are changing the agency's standards for updated COVID-19 booster shots with focus ...
The Community Voice59m
FDA Approves Novavax COVID-19 Shot with Restrictions
The FDA has granted full approval for Novavax's COVID-19 vaccine, but with restrictions. Discover the details now.
BofA Reiterates Hold Rating on Novavax (NVAX) Stock
The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from ...
COVID Vaccine Rule Changes Proposed: What To Know In NY
A previous federal policy recommended an annual COVID shot for all Americans six months and older. Here is what the new proposal would be.
Who can get updated COVID vaccines this fall? FDA will OK for high-risk groups, calls for new clinical trials
The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...
Infectious Disease Advisor4h
FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...
Explore more
Victoria Advocate5h
FDA Limits COVID-19 Boosters to Seniors, Other High-Risk Groups
WEDNESDAY May 21, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has decided that only seniors and ...
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...
BioSpace8h
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director ...